OncoMatch/Clinical Trials/NCT06868485
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Is NCT06868485 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including WSD0922-FU Tablets, Dose level A and WSD0922-FU Tablets, Dose level B for non small cell lung cancer.
Treatment: WSD0922-FU Tablets, Dose level A · WSD0922-FU Tablets, Dose level B — This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR c797s
Required: EGFR mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (osimertinib) — first-line
Evidence of radiological disease progression while on a previous continuous treatment with first-line Osimertinib treatment
Cannot have received: investigational agent or other anticancer drug
Any investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment
Lab requirements
Blood counts
Inadequate bone marrow reserve or organ function as demonstrated [excluded]
Inadequate bone marrow reserve or organ function as demonstrated [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- FOMAT Oncology · Oxnard, California
- Cleveland Clinic Weston Hospital · Weston, Florida
- Karmanos Cancer Institute · Detroit, Michigan
- Hackensack Meridian Health-Southern Ocean Medical Center · Manahawkin, New Jersey
- Cleveland Clinic · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06868485 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent or other anticancer drug disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR c797s is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages